FDA Clearance Tracker · P010029-S025
EUFLEXXA (1% Sodium Hyaluronate)
Last checked: Nov 20, 2026Latest source record: Dec 28, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Dec 28, 2017
Approved
Time to decision
191 days
Received Jun 20, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P010029-S025
- Device name
- EUFLEXXA (1% Sodium Hyaluronate)
- Applicant
- Ferring Pharmaceuticals, Inc.
- Applicant location
- Parsippany, NJ
- Received
- Jun 20, 2017
- Decided
- Dec 28, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P010029
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
Approval for BTG (Ferring) to manufacture, package and release Euflexxa at both the BTG (Ferring) and Lifecore facilities.
Source documents
Other decisions for Ferring Pharmaceuticals, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.